Lorecivivint clinical trials
Also written SM04690.
How each study uses lorecivivint is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lorecivivint is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)CompletedPhase 3Biosplice Therapeutics, Inc.NCT05603754Written as Lorecivivint
- 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee OsteoarthritisTerminatedPhase 3Biosplice Therapeutics, Inc.NCT04931667Written as Lorecivivint
- A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the KneeTerminatedPhase 3Biosplice Therapeutics, Inc.NCT04520607Written as Lorecivivint
- MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee OsteoarthritisTerminatedPhase 2Biosplice Therapeutics, Inc.NCT03706521Written as lorecivivint
- Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee OsteoarthritisCompletedPhase 3Biosplice Therapeutics, Inc.NCT03928184Written as Lorecivivint
- Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)CompletedPhase 3Biosplice Therapeutics, Inc.NCT04385303Written as Lorecivivint
- Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedPhase 2Biosplice Therapeutics, Inc.NCT03727022Written as SM04690
- A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedPhase 2Biosplice Therapeutics, Inc.NCT03122860Written as SM04690
- A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis SubjectsCompletedPhase 2Biosplice Therapeutics, Inc.NCT02536833Written as SM04690
- Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersCompletedPhase 1Biosplice Therapeutics, Inc.NCT04598542Written as Lorecivivint (LOR)
- A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc DiseaseTerminatedPhase 1Biosplice Therapeutics, Inc.NCT03246399Written as SM04690
- Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)CompletedPhase 1Biosplice Therapeutics, Inc.NCT02095548Written as SM04690, 0.03mg/2mL
Codes
What other systems call lorecivivint · ClinicalTrials.gg INT000954
- MeSH (NLM) C000627701lorecivivintConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 42EK42WHI5LORECIVIVINTConfirmed FDA, NLM, Wikidata
- Wikidata Q105337463lorecivivintConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166713LorecivivintOne source FDA
- DrugBank DB14883One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627701 | lorecivivint | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 42EK42WHI5 | LORECIVIVINT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105337463 | lorecivivint | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166713 | Lorecivivint | One source FDA |
| DrugBank | DB14883 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.